Introduction
Microvessel density of the bone marrow is increased in patients with active multiple myeloma (MM). It parallels disease progression and correlates with poor prognosis. [1] [2] [3] [4] Myeloma cells express and secrete vascular endothelial growth factor (VEGF) 3, 5, 6 and basic fibroblast growth factor (bFGF), 3, 6, 7 both of which are considered potent angiogenic cytokines 8 and are likely to contribute to the increased angiogenic potential of bone marrow plasma cells in progressive MM. 3 We and others have previously shown that VEGF derived from myeloma cells stimulates bone marrow stromal cells (BMSC) to produce and secrete interleukin-6
(IL-6), 5, 9 an important growth and survival factor for human MM. [10] [11] [12] Conversely, IL-6
enhances the production and secretion of VEGF by myeloma cells. 5 Besides this paracrine circuit, VEGF may also directly mediate myeloma cell proliferation and migration. 13, 14 Basic FGF concentrations have also been shown to be increased in plasma cell lysates, 3 bone marrow, 15 and peripheral blood 16 of patients with active MM. In the present study, we have therefore addressed the question whether bFGF, besides its proangiogenic activity, also has a role in paracrine tumor-stromal cell interactions in MM.
only.
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Materials and methods

Patients and control subjects
Bone marrow samples from 18 patients with active MM were studied. For control experiments, marrow aspirates were obtained from three healthy volunteers and one lymphoma patient without marrow involvement. B lymphocytes were isolated from the peripheral blood of healthy volunteers (n=3). Patients and volunteers gave informed written consent prior to the sampling procedure.
Immunofluorescent labeling and cell sorting
Anti-CD38-phycoerythrin/cyanin5 was purchased from Coulter-Immunotech (Hamburg, Germany). Anti-CD14 conjugated to phycoerythrin and anti-CD19-fluorescein isothiocyanate were obtained from Becton Dickinson (Heidelberg, Germany), and anti-CD138-fluorescein isothiocyanate was obtained from Serotec (Oxford, UK).
Murine monoclonal antibodies against human CD54, CD68, CD31, and thrombomodulin were purchased from DAKO (Glostrup, Denmark) and used for phenotypic characterization of BMSC.
Bone marrow MNCs were separated by density gradient centrifugation using Ficoll-Paque at 1172 x g for 20 minutes (Pharmacia, Upsala, Sweden). The remaining cells that were negative for the myeloma phenotype were defined as the nontumor cell fraction. CD19 + /CD14 -B lymphocytes were sorted from peripheral blood MNCs of healthy volunteers. On reanalysis, sorted populations had a purity of at least 95% (95.0 % -99.8 %) for the defining phenotype.
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Cell cultures
The human myeloma-derived cell lines RPMI-8226, U-266, and OPM-2 were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). KMS-11 and KMS-18 were kindly provided by T. Otsuki, Kawasaki Medical School, Okayama, Japan. Cell lines, marrow MNC, and sorted marrow myeloma cells from MM patients were cultured in RPMI-1640 medium with 10% fetal calf serum (FCS; Gibco-BRL, Eggenstein, Germany). Cultures of bone marrow stromal cells from MM patients (MM-BMSC) or control subjects (control-BMSC) were established from the MNC fraction of marrow aspirates according to the method of Lagneaux et al 17 with minor modifications. In brief, 5 × 10 5 cells/mL were cultured in minimal essential medium (MEM-alpha, Gibco -BRL) supplemented with 10% FCS in 75-cm 2 flasks. The culture medium was replaced twice weekly until a confluent monolayer had developed (usually after 4-8 weeks). All culture media were supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin (Biochrom, Berlin, Germany), and 2 mmol/L L-glutamine (GIBCO-BRL). Cultures were maintained at 37°C and 5% CO 2 .
For stimulation experiments, BMSC in passages 2 to 4 were grown in 24-well plates. Prior to stimulation, confluent layers were starved for 12 hours (1% FCS).
During the stimulation period, BMSC were kept in serum-free conditions.
Co-cultures were established using a transwell system (pore size 0.4 µm, Nunc, Wiesbaden, Germany) with myeloma cells seeded in the inserts at a density of 2 × 10 6 /mL and confluent BMSC growing on the bottom of the plates. The co-cultures were maintained for 72 hours in serum-free conditions. This system precluded direct cell -cell contact between different cell types.
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Stimulation of cell cultures
BMSC were stimulated with different concentrations of recombinant human bFGF (Boehringer, Mannheim, Germany) for 12, 24, 48, and 72 hours in serum-free conditions. Inhibition experiments were performed using a neutralizing polyclonal goat anti-human anti-bFGF antibody (R&D Systems, Wiesbaden, Germany, 40 µg/mL). Thereafter, cells were pelleted and the supernatants were analyzed for IL-6.
From BMSC pellets, total RNA was isolated for analysis of IL-6 transcripts. IL-6 concentrations in culture supernatants were determined by a commercial enzymelinked immunosorbent assay (ELISA; Quantikine , R&D Systems) with a lower detection limit of 0.7 pg/mL. Calibration curves were prepared by dilution of the IL-6 standard provided by the manufacturer in culture medium. Concentrations of IL-6 are presented as pg/mL corrected for 10 5 cells.
Myeloma cell lines and sorted marrow myeloma cells at a concentration of 1 × 10 6 cells/mL were stimulated with recombinant human IL-6 (PeproTech, Rocky Hill, NJ) at concentrations up to 10 ng/mL. For inhibition experiments, a monoclonal mouse anti-human IL-6 neutralizing antibody was used (R&D Systems, 1.5 -5 µg/mL). After 72 hours of stimulation, cells were harvested and centrifuged, and the supernatants were analyzed for bFGF. From pelleted cells, total RNA was isolated for analyses of bFGF transcripts. Basic FGF levels in culture supernatants were determined by a commercial ELISA (ELISA; Quantikine , R&D Systems). The lower detection limit of the assay is 3 pg/mL. Calibration curves were prepared in culture medium by dilution of the bFGF standard provided by the manufacturer. Basic FGF concentrations in supernatants are presented as pg/mL corrected for 10 6 cells. 
RT-PCR analyses
Transcripts were amplified using Taq polymerase (Promega, Madison, WI) on a Hybrid thermocycler (MWG-Biotech, Ebersberg, Germany) for 35 cycles as follows:
at 94°C for 45 seconds, at 55°C for 45 seconds, and at 72°C for 45 seconds.
Basic In all PCR amplifications, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was co-amplified as an internal control for RNA integrity, using as primers 5´-GAA GGT GAA GGT CGG AGT C-3´ (sense) and 5´-GAA GAT GGT GAT GGG ATT TC-3´ (antisense). GAPDH annealing temperature was modified to 53°C for 45 seconds.
A marker containing a 100 bp DNA ladder (Fermentas, Hannover, MD) served as PCR product length control.
All PCR-amplified products were separated on 6% polyacrylamide gels (Bio-rad, Hercules, CA) and stained with ethidium bromide (Oncor, Gaithersburg, MD). For the estimation of semiquantitative gene expression, the corresponding signals were normalized against GAPDH, using a fluorometric analysis system (Gel Doc 1000; Bio-Rad Laboratories, München, Germany).
Quantitative real-time polymerase chain reaction
Quantitation of mRNA levels for bFGF and IL-6 was also carried out by means of the 5' nuclease assay real-time fluorescence detection method [20] [21] [22] . Briefly, cDNA was amplified by RT-PCR in the ABI prism 7700 sequence detector (PE Biosystems, Foster City, CA). Oligonucleotide probes annealed to the PCR products during the annealing and extension steps. The probes were labeled at the 5' end with VIC only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From (GAPDH) or FAM (bFGF and IL-6, respectively) and at the 3' end with TAMRA which served as a quencher. The 5' to 3' nuclease activity of the Taq polymerase cleaved the probe and released the fluorescent dyes (VIC or FAM), which were detected by the laser detector of the sequencer. After the detection threshold was reached, the fluorescence signal was proportional to the amount of PCR product generated.
Primer and probe sequences were designed with Primer Express software (PE Biosystems) using published sequences. GAPDH primer pairs: 5´-GAA GGT GAA GGT CGG AGT C-3´ (sense), 5´-GAA GAT GGT GAT GGG ATT TC-3´ (antisense); The primer combinations produced a single product of the appropriate length as visualized by electrophoresis in a 6% polyaycrylamide gel. When genomic DNA was used as a template, no bands were seen after PCR amplification. All probes were positioned across exon-exon junctions. Gene expression levels were calculated by means of standard curves generated by serial dilutions of U-266 cDNA or BMSC cDNA. The relative amounts of gene expression were calculated by using the expression of GAPDH as an internal standard. GAPDH expression was stable during stimulation and co-culture experiments. RT-PCR data are presented as means of at least two independent analyses. 
Results
Expression and secretion of bFGF by myeloma cells
In accordance with earlier reports [3] [4] [5] , bFGF mRNA transcripts were detected by RT-PCR in the myeloma-derived cell lines RPMI-8226, U-266, KMS-11, and KMS-18 ( Figure 1A ) and in purified CD38 pg/mL; IQR, 4.9-11.3 pg/mL; P < . 05, Mann-Whitney test) and undetectable in OPM-2.
Basic FGF levels in the culture media of ficolled marrow MNC from MM patients (n = 18; median 13.5 pg/mL; IQR, 11.7-17.6 pg/mL) were similar to those measured ex vivo in the cell-free supernatants of untreated marrow aspirates (median 27.7 pg/mL; IQR, 12.4-115.8 pg/mL) and significantly higher than in the media of marrow MNC from control subjects (n = 4; median and IQR 0.0 pg/mL; P < .02; see Figure 4 ). 47.7 pg/mL) were found to be significantly higher than in the media of non-tumor cells (median 0.4 pg/mL; IQR 0.0-0.7 pg/mL; P < .0001; Figure 4 ). These results identified myeloma cells as the major source of bFGF in MM bone marrow.
FGF receptors in myeloma and marrow stromal cells
The expression of the high affinity FGF receptors R1 through R4 was analyzed by flow cytometric phenotyping and RT-PCR in U-266, RPMI-8226, and OPM-2 cells.
As shown for U-266 in Figures 5A ( Figure 5C , UPN #47).
BMSC derived from both MM patients and control subjects expressed FGF-R1 through R4 (representative results in Figure 5D ).
Basic FGF stimulates IL-6 expression and secretion in MM-BMSC and control-BMSC
BMSC cultures were established from bone marrow aspirates of 13 patients with multiple myeloma (MM-BMSC) as previously described. 5 Stimulation of BMSC only.
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Effects of IL-6 on bFGF expression and secretion in myeloma cells
To analyze whether IL-6 would in turn stimulate the secretion of bFGF by myeloma cells, U-266 and RPMI-8226 myeloma cell lines were cultured for 72 hours in the absence or presence of exogenous IL-6 (10 ng/mL) ± ± ± ± anti-human IL-6 antibody (1.5 µg/mL) ( Figure 7) . A 2-fold increase in bFGF concentrations was observed in culture supernatants of both cell lines, which was completely inhibited in the presence of an IL-6-neutralizing antibody.
Next, myeloma cells sorted from bone marrow aspirates of 18 MM patients were cultured in the presence or absence of IL-6 (10 ng/mL) for 72 hours. Although highly variable, IL-6 stimulated the bFGF secretion into culture supernatants up to 3.6-fold (median 1.5 fold, P < .002; Figure 8A ). In line with these results, an increase in bFGF mRNA levels was observed in IL-6-stimulated marrow myeloma cells using quantitative RT-PCR ( Figure 8B ). As shown for a representative patient, this effect of IL-6 could again be completely inhibited by the IL-6 neutralizing antibody.
For
Upregulation of IL-6 and bFGF in transwell co-cultures of myeloma and marrow stromal cells
To further support the hypothesis of an enhancing interaction between bFGF and IL-6 within the marrow of myeloma patients, we studied the mutual effects of cocultivation of myeloma and marrow stromal cells on IL-6 and bFGF sec retion. In order to preclude direct myeloma to stromal cell contacts, we chose a transwell co-culture system. In this series of experiments, BMSC from MM patients were co-cultured with For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From increased bFGF production by myeloma cells was likely to account for at least part of the bFGF increase ( Figure 9B, insert) However, in contrast to VEGF, little is known about potential autocrine and paracrine pathways triggered by bFGF. Therefore, the present study aimed at investigating the contribution of bFGF to paracrine IL-6 secretion from stromal cells in the marrow microenvironment.
Our findings corroborate previous reports demonstrating that various myelomaderived cell lines, except OPM-2, as well as purified marrow myeloma cells from patients express and secrete bFGF. 3, 6, 26, 27 The present data extend these observations in that they identify myeloma cells as the prevailing source of bFGF in the bone marrow of patients with active MM (see Figure 4) . The latter results would explain that bFGF concentrations in marrow aspirates and peripheral blood have been found to correlate with MM disease activity. 15, 16, 29 Signaling of bFGF is mediated by a familiy of tyrosine kinase receptors comprising FGF -R1 through FGF-R4 and the recently described FGF-R5. [30] [31] [32] [33] [34] [35] These receptors transduce signals related to cell growth, differentiation, tissue modeling, and angiogenesis. [36] [37] [38] Binding of bFGF to one of its receptors requires the interaction with heparan sulfate proteoglycans like syndecan-1, which is present on the surface of myeloma cells and in their stromal environment. [39] [40] [41] [42] In the cell lines RPMI-8226 only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From and U-266 and in purified myeloma cells from patients, we could demonstrate expression of the high affinity FGF receptors R1 through R4. Although not addressed in the present study, the simultaneous expression of bFGF and its high affinity receptors by myeloma cells gives rise to the speculation on an autocrine loop as it was recently described for VEGF. 13 As an exception, predominant expression of FGF -R3 was evident in those patient cells and myeloma cell lines (OPM-2, KMS-11, KMS-18) carrying the translocation t(4;14), which is known to result in dysregulated expression of the receptor gene. 7, 43 FGF-R5 expression by myeloma and stromal cells was not studied in the present series and thus cannot be excluded.
In line with earlier reports on marrow stromal cells in humans, 44 we also showed expression of FGF-R1 through R4 in BMSC from control subjects and MM patients, indicating that paracrine bFGF signaling in the marrow microenvironment may occur.
As previously described, the BMSC cultures used in our experiments mainly consisted of CD54 + fibroblast-like cells with few CD68 + macrophages, but without CD31 or thrombomodulin reactive endothelial cells. 5, 45 Thus, the observations on bFGF-induced IL-6 release from BMSC indicate that paracrine bFGF effects do not depend on the presence of microvascular endothelium in the vicinity of the tumor. Similar to the previously described effects of VEGF 121 and VEGF 165 , 5 our results demonstrate that bFGF induces a time-and dose-dependent increase in IL-6 secretion by BMSC. These findings suggest that bFGF is not only an angiogenic growth factor in MM, but also functions as a cytokine supporting myeloma cell growth and survival by paracrine stimulation of IL-6 release from the marrow stroma.
The IL-6 release induced by bFGF appears to be less pronounced than that reported for VEGF. 5 In addition, although bFGF effects were observed with concentrations as low as 1 ng/mL, these concentrations are still one order of magnitude higher than those measured in culture supernatants of myeloma cells.
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Besides bFGF and VEGF, myeloma cells have been shown to secrete cytokines including transforming growth factor-(TGF-), tumor necrosis factor-(TNF-), and interleukin-1 (IL-1 ) which are capable of stimulating IL-6 secretion by marrow stromal cells. [46] [47] [48] [49] In order to rule out an effect of such cytokines, bFGF stimulations of cultured BMSC were performed under serum-free conditions. Apart from these humoral mediators, adhesion of myeloma cells to bone marrow stroma has also been shown to potently stimulate IL-6 secretion. In analogy to the data reported on VEGF, 5 we were also able to demonstrate reciprocal stimulation of bFGF transcription and secretion in myeloma cells by IL-6.
This effect and its specific inhibition by anti-IL-6 antibodies was observed in cell lines,
i.e. U-266 and RPMI-8226, and in purified marrow myeloma cells from some, but not all MM patients. In line with the findings in IL-6-stimulated myeloma cell monocultures, the transwell co-culture experiments revealed a significant supraadditive increase in bFGF release when myeloma cells were cultured in the only.
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Finally, the question arises whether the bFGF release into co-culture supernatants is entirely derived from myeloma cells. As mentioned above, cell sorting studies revealed myeloma cells to be the primary source of bFGF in the marrow of patients with active MM. In addition, we only detected trace amounts of bFGF in supernatants of BMSC monocultures (compare Figures 4, 9, and 10) . Therefore, we tend to attribute the increase of bFGF in co-cultures and the related effects on IL-6 to enhanced bFGF secretion by myeloma cells. Support of this interpretation comes from a preliminary report by Van Riet et al., demonstrating that BMSC conditioned media induced a five-fold increase in bFGF production by the myeloma cell lines MMs.1 and U-266, while co-cultivation with MM cell lines had no effect on the stromal production of bFGF. 26 None the less, there is some controversy as to the relative contributions of BMSC and myeloma cells to bFGF secretion. Gupta et al. showed that cultured BMSC are equally and sometimes more potent than myeloma cells in releasing bFGF. In their study, binding of myeloma cells to BMSC decreased, rather than increased bFGF concentrations in culture supernatants. 9 Considering that we used transwell co-cultures precluding adherence of myeloma cells to BMSC, our findings in co-cultures are not necessarily conflicting with this report since they merely reflect the effect of humoral mediators on bFGF release. However, our experiments cannot exclude an additional induction of bFGF secretion from BMSC by yet unidentified myeloma-derived mediators. After all, this possibility would not detract from the observation that bFGF, be it derived from myeloma or stromal cells, is a biologically relevant paracrine mediator of IL-6 secretion by marrow stromal cells.
Taken together, the mutual stimulation of bFGF and IL-6 strongly suggests a role for bFGF in paracrine interactions between myeloma and marrow stromal cells, similar to the role previously described for VEGF. 5 These findings are particularly relevant in view of new treatment strategies for MM targeting marrow neovascularization or angiogenic cytokines and their receptors. [54] [55] [56] only.
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